Optimizing Site of Conjugation Modulates ADC Efficacy & Reducing Toxicity for Complex Immuno-Oncology Payloads & Formats
Time: 2:00 pm
day: Conference Day Two
Details:
- Complex payloads require a site-selective approach to identify optimal conjugates with the widest therapeutic index possible. Finding the right site of conjugation, which varies by payload, can increase the TI by >5-fold via both MED and MTD improvements
- Unique drug conjugate compositions, such as multi-payload conjugates, benefit from unique and orthogonal chemistries to enable one-pot reactions and efficient ADC production
- The ADC field will benefit from expanding payload options and formats to better address specific oncology indications. However, these novel drug substances require a platform capable of producing candidate variants for high throughput screening during discovery, but also transition to CMC-friendly scalable platforms for manufacturing
